Advertisement

European Journal of Clinical Pharmacology

, Volume 55, Issue 9, pp 633–637 | Cite as

Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects

  • M. Burnier
  • A. F. Fricker
  • D. Hayoz
  • J. Nussberger
  • H. R. Brunner
PHARMACOKINETICS AND DISPOSITION

Abstract

Objective: The pharmacokinetic and pharmacodynamic properties of YM087, (4′-[(2-methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepin-6-yl)-carbonyl]-2-phenylbenzanilide monohydrochloride), a new orally active, dual V1/V2 receptor antagonist were characterised in healthy normotensive subjects.

Methods: Six subjects were randomly allocated to receive, at 1-week intervals, a single oral dose of 60 mg YM087 and a single i.v. dose of 50 mg YM087 in an open-label, crossover study.

Results: YM087 had an oral bioavailability of 44% and a short half-life. Upon oral and i.v. administration of YM087, a significant sevenfold increase in urine flow rate and a fall in urinary osmolality (from 600 mosmol/l to less than 100-mosmol/l) were observed with a peak effect 2 h after drug intake suggesting effective vasopressin V2 receptor blockade. Simultaneously, significant increases in plasma osmolality (from 283 ± 1.3 mosmol/l to 288 ± 1.0 mosmol/l after i.v. and from 283 ± 2.1 mosmol/l to 289 ± 1.7-mosmol/l after oral administration) and vasopressin levels (from 1.5 ± 0.3 pg/ml to 3.7 ± 0.6 pg/ml after i.v. and from 0.9 ± 0.1 pg/ml to 3.9 ± 0.7 pg/ml after oral administration) were found. When administered i.v., YM087 inhibited the vasopressin-induced skin vasoconstriction, suggesting a blockade of V1 receptors. However, the YM087-induced antagonism of V1 receptors was less pronounced than V2 receptor blockade.

Conclusion: These data show that YM087 is an effective dual V1/V2 receptor antagonist in man.

Key words YM087 Vasopressin Receptor antagonist 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer-Verlag Berlin Heidelberg 1999

Authors and Affiliations

  • M. Burnier
    • 1
  • A. F. Fricker
    • 1
  • D. Hayoz
    • 1
  • J. Nussberger
    • 1
  • H. R. Brunner
    • 1
  1. 1.Division of Hypertension and Vascular Medicine, Department of Medicine, Rue P. Decker, CHUV, CH-1011 Lausanne, Switzerland e-mail: Michel.Burnier@chuv.hospvd.ch Tel.: +41-21-3140750; Fax: +41-21-3140761CH

Personalised recommendations